Immunome, Inc. and _____________, As Warrant Agent Form of Preferred Stock Warrant Agreement Dated As Of __________ Immunome, Inc. Form of Preferred Stock Warrant AgreementPreferred Stock Warrant Agreement • February 13th, 2024 • Immunome Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 13th, 2024 Company Industry JurisdictionThis Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between Immunome, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
Immunome, Inc. and _____________, As Warrant Agent Form of Common Stock Warrant Agreement Dated As Of __________ Immunome, Inc. Form of Common Stock Warrant AgreementCommon Stock Warrant Agreement • February 13th, 2024 • Immunome Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 13th, 2024 Company Industry JurisdictionThis Common Stock Warrant Agreement (this “Agreement”), dated as of [●], between Immunome, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under the laws of [●] and having a corporate trust office in [●], as warrant agent (the “Warrant Agent”).
Immunome, Inc. and _____________, As Warrant Agent Form of Debt Securities Warrant Agreement Dated As Of __________ Immunome, Inc. Form of Debt Securities Warrant AgreementDebt Securities Warrant Agreement • February 13th, 2024 • Immunome Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 13th, 2024 Company Industry JurisdictionThis Debt Securities Warrant Agreement (this “Agreement”), dated as of [·], between Immunome, Inc., a Delaware corporation (the “Company”), and [·], a [corporation] [national banking association] organized and existing under the laws of [·] and having a corporate trust office in [·], as warrant agent (the “Warrant Agent”).
STOCK ISSUANCE AGREEMENTStock Issuance Agreement • February 13th, 2024 • Immunome Inc. • Pharmaceutical preparations • New York
Contract Type FiledFebruary 13th, 2024 Company Industry JurisdictionThis Stock Issuance Agreement (“Agreement”) is entered into as of January 5, 2024, by and between Zentalis Pharmaceuticals, Inc., a Delaware corporation having offices at 1359 Broadway, Suite 801, New York, NY 10018 (“Zentalis”), and Immunome, Inc. a Delaware corporation having an office at 665 Stockton Drive, Suite 300, Exton, PA 19341 (“Immunome”). The capitalized terms used herein and not otherwise defined have the meanings given to them in Appendix 1 or the License Agreement.